Disease areas

Autoimmune and inflammatory diseases

53 public biotech companies we cover are developing treatments for rheumatoid arthritis, lupus, Sjögren's disease, gout, transplant rejection and other immune conditions. 25 upcoming catalysts are listed below, with dates as the companies gave them.

Companies

Drug pages

Obecabtagene autoleucel (obe-cel)Mivocabtagene autoleucel (miv-cel)

Upcoming catalysts

Firm dates · a specific day set by the company or regulator

Next 30 days

Later

Estimated timing · a month, quarter, half-year or year-end the company gave

Expected in December 2026

Expected in Q4 2026

Expected in H2 2026

Expected by end of 2026

Expected in February 2027

  • February 2027
    YUTREPIA · Phase 2a topline results (RE-WARM) · Raynaud's phenomenon associated with systemic sclerosis (SSc-RP)

Expected in Q1 2027

Expected by end of March 2027

Expected in H1 2027

Expected in Q3 2027

Other disease areas